교보문고 SCHOLAR 스콜라
이 자료는 국가지식 연계기관과의 협약에 따라 무료로 제공됩니다.
원문을 이용하시기 위해서는 연계기관의 정책을 따르고 있으니
궁금하신 사항은 연계기관을 통해 문의하시기 바랍니다.
곧 연계기관으로 이동합니다
본문내용 바로가기
홈 > 대한노인정신의학회 > 노인정신의학

알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가

: 12개월 추적관찰 연구

Comparative Assessment of Clinical Efficacy between the Naive and the Switching Group to Donepezil:12 Months Prospective Study

강효신(Hyo Shin Kang) , 안인숙(Inn Sook Ahn) , 윤지혜(Ji Hae Yun) , 문유진(Yu Jin Moon) , 황태영(Tae Young Hwang) , 이영민(Young Min Lee) , 김혜란(Hyeran Kim) , 정재원(Jae Won Chung) , 김도관(Doh Kwan Kim)

간행물명 : 노인정신의학
권/호 : 노인정신의학 제14권 제2호 / 2010 / 111~117 (7pages)
발행기관 : 대한노인정신의학회
간행물유형 : 학술저널
주제분류 : 정신과학
파일형식 : PDF
원문보기 원문저장 공유하기 인용정보 구매하기
3,000원

초록

영어 초록
Objectives : The purpose of this study was to compare the efficacy between switching patients with Alzheimer's disease (AD) from galantamine or rivastigmine to donepezil because they were not responding adequately, and naive patients with AD who initiated therapy with donepezil. Methods : A total of 108 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients' activities of daily living using Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL);behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results : 86 naive patients and 22 switching patients were enrolled in the study. 74 patients completed the study and 34 discontinued their treatment before week 52. There was no significant difference between two patient groups in demographic data, baseline characteristics and dementia severity except duration of illness. The total ADAS-cog-K scores were not significantly different from baseline after 52 weeks of treatment in both groups. Both groups demonstrated deterioration of S-ADL and S-IADL at 52 weeks. The NPI scores did not significantly change in both groups. Based on the operational criteria, 61.6% of the naive group and 54.5% of the switching group were responders to donepezil. Conclusion : The switching group had similar levels of efficacy with the naive group who initiated therapy with donepezil. These results suggest that patients not responding adequately to rivastigmine or galantamine may improve or stabilize after switching to donepezil and prior medication does not effect donepezil's efficacy.

목차

서 론
방 법
결 과
고 찰